antares
pharma
reports
strong
third
quarter
financial
operating
results
third
quarter
revenue
increases
million
third
quarter
net
income
million
eps
ewing
globe
newswire
antares
pharma
nasdaq
atrs
company
pharmaceutical
technology
company
today
reported
financial
operating
results
third
quarter
ended
september
record
revenue
million
net
income
million
earnings
per
share
company
also
reported
record
revenue
million
increase
versus
first
nine
months
excited
report
another
quarter
strong
financial
results
illustrate
significant
growth
across
diversified
business
proprietary
partner
revenue
total
revenue
increased
almost
million
primarily
driven
strong
demand
xyosted
teva
generic
epipen
xyosted
continues
represent
biggest
growth
driver
quarterly
growth
growth
total
prescriptions
compared
periods
believe
ongoing
challenges
patients
physicians
due
pandemic
support
increased
demand
painless
testosterone
replacement
therapy
also
remain
committed
development
internal
pipeline
focused
urology
endocrinology
excited
recent
licensing
nocdurna
immediately
expands
proprietary
portfolio
offering
leverages
existing
salesforce
given
significant
overlap
urology
call
points
said
robert
apple
president
chief
executive
officer
antares
pharma
furthermore
development
pipeline
partners
believe
underappreciated
opportunities
generic
teriparatide
launched
european
countries
canada
israel
teva
remain
eager
potential
approval
also
look
forward
idorsia
initiating
phase
trial
selatogrel
pen
able
provide
timeline
pfizer
program
look
ahead
overall
believe
diversified
business
continue
advance
support
future
aggressive
growth
apple
concluded
third
quarter
recent
highlights
reported
third
quarter
total
revenue
million
increase
compared
million
period
last
year
proprietary
product
revenue
increased
million
compared
million
third
quarter
total
partnered
product
development
royalty
revenue
million
third
quarter
compared
million
third
quarter
representing
increase
reported
third
quarter
net
income
million
earnings
per
share
compared
net
income
million
earnings
per
share
comparable
period
last
year
xyosted
total
prescriptions
third
quarter
increased
sequentially
according
iqvia
total
prescriptions
third
quarter
increased
sequentially
according
iqvia
entered
exclusive
license
agreement
ferring
pharmaceuticals
marketed
urology
product
desmopressin
acetate
indicated
treatment
nocturia
due
nocturnal
polyuria
adults
awaken
least
two
times
per
night
urinate
united
states
third
quarter
financial
results
total
revenue
generated
product
sales
license
development
activities
royalties
million
three
months
ended
september
increase
compared
million
period
nine
months
ended
september
total
revenue
million
increase
million
comparable
period
product
sales
million
three
months
ended
september
increase
compared
million
period
period
ended
september
product
sales
million
increase
million
comparable
period
sales
proprietary
products
generated
revenue
million
million
three
nine
months
ended
september
respectively
compared
million
million
three
nine
months
ended
september
respectively
increase
proprietary
product
sales
three
nine
months
ended
september
respectively
compared
three
nine
months
ended
september
principally
attributable
continued
growth
prescriptions
sales
partnered
product
sales
million
three
months
ended
september
million
million
nine
months
ended
september
respectively
net
decrease
sales
partnered
products
nine
months
ended
september
compared
period
attributable
decreased
sales
devices
ferring
decrease
sales
auto
injectors
amag
reduction
quantities
generic
teriparatide
devices
sold
teva
previous
periods
decreases
offset
increase
sales
teva
generic
epipen
licensing
development
revenue
million
million
three
periods
ended
september
respectively
compared
million
million
comparable
periods
respectively
increase
licensing
development
revenue
nine
months
ended
september
primarily
pfizer
rescue
pen
idorsia
selatogrel
pen
development
programs
royalty
revenue
million
three
months
ended
september
compared
million
period
period
ended
september
royalty
revenue
million
compared
million
period
net
decrease
royalty
revenue
primarily
attributable
decline
royalties
recognized
amag
net
sales
subcutaneous
auto
injectors
offset
increase
royalties
teva
net
sales
epinephrine
injection
usp
gross
profit
million
million
three
months
ended
september
respectively
million
million
nine
months
ended
september
respectively
increase
gross
profit
primarily
attributable
increase
proprietary
product
sales
total
operating
expenses
million
third
quarter
compared
million
comparable
period
total
operating
expenses
nine
months
ended
september
million
compared
million
comparable
period
decrease
operating
expenses
three
periods
compared
periods
primarily
attributable
reduction
sales
marketing
costs
incurred
result
various
orders
travel
restrictions
related
net
income
million
per
share
third
quarter
compared
million
per
share
period
net
income
million
per
share
nine
months
ended
september
compared
net
loss
million
loss
per
share
comparable
period
september
cash
cash
equivalents
investments
million
compared
million
december
cash
generated
operations
million
nine
months
ended
september
compared
cash
used
operations
million
nine
months
ended
september
financial
guidance
company
today
reaffirmed
revenue
guidance
range
million
represents
growth
rate
webcast
conference
call
information
antares
management
team
provide
company
update
review
third
quarter
financial
results
via
conference
call
webcast
today
november
et
eastern
time
webcast
conference
call
include
slide
presentation
accessed
investor
relations
section
company
website
webcasts
presentations
alternatively
callers
may
participate
audio
portion
conference
call
dialing
domestic
callers
international
callers
callers
reference
antares
pharma
conference
call
conference
id
number
antares
pharma
antares
pharma
pharmaceutical
technology
company
focused
primarily
development
commercialization
injectable
pharmaceutical
products
using
advanced
drug
delivery
auto
injector
technology
company
portfolio
proprietary
partnered
commercial
products
several
product
candidates
various
stages
development
well
significant
strategic
alliances
industry
leading
pharmaceutical
companies
including
teva
pharmaceutical
industries
teva
amag
pharmaceuticals
amag
pfizer
pfizer
idorsia
pharmaceuticals
idorsia
antares
pharma
products
include
testosterone
enanthate
injection
methotrexate
injection
subcutaneous
use
sumatriptan
injection
usp
distributed
teva
company
also
markets
desmopressin
acetate
licensed
ferring
pharmaceuticals
safe
harbor
statement
private
securities
litigation
reform
act
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
statements
subject
certain
risks
uncertainties
cause
actual
results
differ
materially
described
factors
may
cause
differences
include
limited
company
ability
achieve
reinstated
revenue
guidance
uncertainty
regarding
duration
scope
severity
pandemic
mitigation
measures
restrictions
implemented
response
impact
demand
products
new
patients
prescriptions
future
revenue
product
supply
overall
business
operating
results
financial
condition
successful
commercialization
united
states
market
acceptance
future
revenue
commercial
success
future
revenue
market
acceptance
teva
generic
epinephrine
product
future
revenue
whether
fda
withdraw
marketing
approval
amag
subcutaneous
auto
injector
following
recent
fda
letter
seeking
withdrawal
whether
amag
granted
appeal
hearing
granted
whether
amag
successful
future
prescriptions
market
acceptance
revenue
teva
ability
successfully
commercialize
sumatriptan
injection
usp
amount
revenue
future
prescriptions
sales
teva
ability
successfully
commercialize
generic
teriparatide
countries
europe
canada
israel
future
revenue
successful
development
including
timing
results
clinical
bridging
phase
clinical
trial
drug
device
combination
product
selatogrel
idorsia
pharmaceuticals
fda
global
regulatory
approvals
future
revenue
fda
approval
teva
pending
anda
generic
forteo
future
revenue
timing
results
company
partners
research
projects
clinical
trials
product
candidates
development
including
pfizer
undisclosed
development
product
actions
fda
regulatory
agencies
respect
company
products
product
candidates
partners
continued
growth
product
development
licensing
royalty
revenue
company
ability
meet
loan
extension
interest
payment
milestones
ability
repay
debt
obligation
hercules
capital
company
ability
obtain
financial
resources
research
development
clinical
commercial
activities
statements
regarding
matters
historical
facts
involve
predictions
statements
involve
known
unknown
risks
uncertainties
factors
may
cause
actual
results
performance
achievements
prospects
materially
different
future
results
performance
achievements
prospects
expressed
implied
statements
cases
identify
statements
terminology
may
would
expect
intend
plan
anticipate
believe
estimate
predict
potential
seem
seek
future
continue
appear
negative
terms
similar
expressions
although
statements
contain
identifying
words
additional
information
concerning
factors
may
cause
actual
results
differ
materially
anticipated
statements
contained
risk
factors
section
company
annual
report
form
company
periodic
reports
filings
securities
exchange
commission
company
cautions
investors
place
undue
reliance
statements
contained
press
release
statements
based
information
currently
available
company
date
hereof
company
undertakes
obligation
revise
update
statements
reflect
events
circumstances
date
press
release
except
required
law
contact
tram
bui
vice
president
corporate
communications
investor
relations
tbui
tables
follow
antares
pharma
table
consolidated
condensed
statements
operations
amounts
thousands
except
per
share
amounts
unaudited
three
months
ended
nine
months
ended
september
increase
september
increase
decrease
decrease
revenue
product
sales
licensing
development
revenue
royalties
total
revenue
cost
revenue
gross
profit
research
development
selling
general
administrative
total
operating
expenses
operating
income
loss
expense
net
income
loss
net
income
loss
per
common
share
basic
diluted
weighted
average
common
shares
outstanding
basic
diluted
antares
pharma
table
consolidated
detail
revenue
product
sales
amounts
thousands
unaudited
three
months
ended
nine
months
ended
september
september
product
sales
partnered
product
sales
total
product
sales
antares
pharma
table
consolidated
condensed
balance
sheets
amounts
thousands
unaudited
